GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Accumulated other comprehensive income (loss)

Amryt Pharma (Amryt Pharma) Accumulated other comprehensive income (loss) : $247.1 Mil (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Amryt Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2022 was $247.1 Mil.

Amryt Pharma's quarterly Accumulated other comprehensive income (loss) declined from Mar. 2022 ($247.2 Mil) to Jun. 2022 ($242.0 Mil) but then increased from Jun. 2022 ($242.0 Mil) to Sep. 2022 ($247.1 Mil).

Amryt Pharma's annual Accumulated other comprehensive income (loss) increased from Dec. 2019 ($194.2 Mil) to Dec. 2020 ($236.5 Mil) and increased from Dec. 2020 ($236.5 Mil) to Dec. 2021 ($246.3 Mil).

Amryt Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Amryt Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Accumulated other comprehensive income (loss) Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.81 -31.34 194.24 236.49 246.30

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 194.66 246.30 247.23 242.00 247.12

Amryt Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Amryt Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
TARO COLL AVDL DCPH HROW ANIP PAHC DVAX PROC EOLS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 SZSE:000538 TSE:4507 SHSE:600085 SHSE:600196
Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Website
http://www.amrytpharma.com
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).